OA02.07 Updated Results of Phase 1 Study of DS-8201a in HER2-Expressing or –Mutated Advanced Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.244
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P1.01-41 a Phase 2 Study of DS-8201a in HER2-Overexpressing or -Mutated Advanced Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Phase II Study of S-1 and Docetaxel for Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2010English

MA04.09 Neoadjuvant Atezolizumab in Resectable Non-Small Cell Lung Cancer (NSCLC): Updated Results From a Multicenter Study (LCMC3)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

TG4010 Immunotherapy Combined With First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Phase IIb Results of the TIME Study

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2014English

Targeting HER2 Aberrations in Non-Small Cell Lung Cancer With Osimertinib

Clinical Cancer Research
Cancer ResearchOncology
2018English

HER2 Mutations in Chinese Patients With Non-Small Cell Lung Cancer

Oncotarget
Oncology
2016English

Afatinib Treatment in Advanced Non-Small Cell Lung Cancer

Lung Cancer: Targets and Therapy
Oncology
2011English

Patient-Reported Outcomes From FLAURA: Osimertinib Versus Erlotinib or Gefitinib in Patients With EGFR-mutated Advanced Non-Small-Cell Lung Cancer

European Journal of Cancer
Cancer ResearchOncology
2020English

Advanced Non-Small Cell Lung Cancer in Elderly Patients

Breathe
PulmonaryRespiratory Medicine
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy